We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Fragment-based Drug Discovery Platform Announced between IOTA and Beactica
News

New Fragment-based Drug Discovery Platform Announced between IOTA and Beactica

New Fragment-based Drug Discovery Platform Announced between IOTA and Beactica
News

New Fragment-based Drug Discovery Platform Announced between IOTA and Beactica

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Fragment-based Drug Discovery Platform Announced between IOTA and Beactica"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Two fragment-based drug discovery (FBDD) companies have announced a new commercial alliance. IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Beactica AB, based in Uppsala, Sweden, will join forces to deploy a proprietary FBDD-based lead discovery and optimization platform.

The IOTA-Beactica platform couples site-directed FBDD libraries to fragment and lead screening using surface plasmon resonance (SPR) biosensor technology, enabling progression of new discovery programs from concept to optimized lead.

Based on determination of ligand-target interaction information, and using a combination of fragment-based drug screening and medicinal chemistry-led design approaches, applicable to a wide range of new targets, the platform will initially focus on the development of new classes of kinase inhibitors. The reagents, tools and technologies developed by the two companies will be commercialized through drug discovery partnerships with pharmaceutical companies active in the kinase area.

Dr Per Kallblad, CEO of Beactica, said, "We are delighted to work with IOTA to expand our existing drug discovery platform. The combination of IOTA's proprietary FBDD engine with Beactica's SPR screening technology will be an excellent way to pursue the discovery and optimization of new kinase inhibitors."

Dr David Bailey, heading IOTA, commented, "Fragment-based drug discovery is a fast, efficient and productive route to NCE discovery. Our combined technologies offer a comprehensive lead discovery solution to our pharma partners."

Advertisement